Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000129481 | SCV000184251 | uncertain significance | Hereditary cancer-predisposing syndrome | 2015-06-09 | criteria provided, single submitter | clinical testing | The p.K77N variant (also known as c.231A>T), located in coding exon 3 of the NF1 gene, results from an A to T substitution at nucleotide position 231. The lysine at codon 77 is replaced by asparagine, an amino acid with similar properties. This variant was previously reported in the SNPDatabase as rs373563053. Based on data from the NHLBI Exome Sequencing Project (ESP), the T allele has an overall frequency of approximately 0.01% (1/13002) total alleles studied, having been observed in0.01% (1/8598) European American alleles. This variant was not reported in the 1000 Genomes Project population-based cohort.To date, this alteration has been detected with an allele frequency of approximately 0.01% (greater than 55000 alleles tested) in our clinical cohort.This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis.Since supporting evidence is limited at this time, the clinical significance of p.K77Nremains unclear. |
Labcorp Genetics |
RCV000205241 | SCV000260829 | likely benign | Neurofibromatosis, type 1 | 2025-02-02 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001808397 | SCV002056076 | uncertain significance | not provided | 2024-08-20 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Genome- |
RCV000205241 | SCV002561422 | uncertain significance | Neurofibromatosis, type 1 | 2022-03-15 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002453460 | SCV002735683 | likely benign | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2021-05-28 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Fulgent Genetics, |
RCV002478386 | SCV002790616 | uncertain significance | Neurofibromatosis, familial spinal; Juvenile myelomonocytic leukemia; Neurofibromatosis, type 1; Neurofibromatosis-Noonan syndrome; Café-au-lait macules with pulmonary stenosis | 2022-03-17 | criteria provided, single submitter | clinical testing | |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV001808397 | SCV005624536 | uncertain significance | not provided | 2024-05-14 | criteria provided, single submitter | clinical testing |